Literature DB >> 23425950

Hippocampal abnormalities of glutamate/glutamine, N-acetylaspartate and choline in patients with depression are related to past illness burden.

Javier de Diego-Adeliño1, Maria J Portella, Beatriz Gómez-Ansón, Olga López-Moruelo, Maria Serra-Blasco, Yolanda Vives, Dolors Puigdemont, Rosario Pérez-Egea, Enric Álvarez, Víctor Pérez.   

Abstract

BACKGROUND: Smaller hippocampal volumes in major depressive disorder (MDD) have been linked with earlier onset, previous recurrences and treatment refractoriness. The aim of our study was to investigate metabolite abnormalities in the hippocampus associated with past depressive illness burden.
METHODS: Glutamate/glutamine (Glx), N-acetylaspartate (NAA) and choline (Cho), potential markers of glial/neuronal integrity and membrane turnover, respectively, were measured in adults with depression and healthy controls using a 3 T magnetic resonance spectroscopy scanner. Voxels were placed in the head of the right and left hippocampus. We controlled for systematic differences resulting from volume-of-interest (VOI) tissue composition and total hippocampal volume.
RESULTS: Our final sample comprised a total of 16 healthy controls and 52 adult patients with depression in different stages of the illness (20 treatment-resistant/chronic, 18 remitted-recurrent and 14 first-episode), comparable for age and sex distribution. Patients with treatment-resistant/chronic and remitted-recurrent depression had significantly lower levels of Glx and NAA than controls, especially in the right hippocampal region (p ≤ 0.025). Diminished levels of Glx were correlated with longer illness duration (left VOI r = -0.34, p = 0.01). By contrast, Cho levels were significantly higher in patients with treatment-resistant/chronic depression than those with first-episode depression or controls in the right and left hippocampus (up to 19% higher; all p ≤ 0.025) and were consistently related to longer illness duration (right VOI r = 0.30, p = 0.028; left VOI r = 0.38, p = 0.004) and more previous episodes (right VOI r = 0.46, p = 0.001; left VOI r = 0.44, p = 0.001). LIMITATIONS: The cross-sectional design and the inclusion of treated patients are the main limitations of the study.
CONCLUSION: Our results support that metabolite alterations within the hippocampus are more pronounced in patients with a clinical evolution characterized by recurrences and/or chronicity and add further evidence to the potential deleterious effects of stress and depression on this region.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23425950      PMCID: PMC3581591          DOI: 10.1503/jpn.110185

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  33 in total

1.  Quantitative MRI of the hippocampus and amygdala in severe depression.

Authors:  E Mervaala; J Föhr; M Könönen; M Valkonen-Korhonen; P Vainio; K Partanen; J Partanen; J Tiihonen; H Viinamäki; A K Karjalainen; J Lehtonen
Journal:  Psychol Med       Date:  2000-01       Impact factor: 7.723

2.  Automatic quantitation of localized in vivo 1H spectra with LCModel.

Authors:  S W Provencher
Journal:  NMR Biomed       Date:  2001-06       Impact factor: 4.044

3.  Verbal and visual memory performance and hippocampal volumes, measured by 3-Tesla magnetic resonance imaging, in patients with Cushing's syndrome.

Authors:  Eugenia Resmini; Alicia Santos; Beatriz Gómez-Anson; Yolanda Vives; Patricia Pires; Iris Crespo; Maria J Portella; Manel de Juan-Delago; Maria-José Barahona; Susan M Webb
Journal:  J Clin Endocrinol Metab       Date:  2011-12-07       Impact factor: 5.958

4.  Substance P receptor antagonist and clomipramine prevent stress-induced alterations in cerebral metabolites, cytogenesis in the dentate gyrus and hippocampal volume.

Authors:  M G C van der Hart; B Czéh; G de Biurrun; T Michaelis; T Watanabe; O Natt; J Frahm; E Fuchs
Journal:  Mol Psychiatry       Date:  2002       Impact factor: 15.992

5.  Hippocampal apoptosis in major depression is a minor event and absent from subareas at risk for glucocorticoid overexposure.

Authors:  P J Lucassen; M B Müller; F Holsboer; J Bauer; A Holtrop; J Wouda; W J Hoogendijk; E R De Kloet; D F Swaab
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

6.  Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine.

Authors:  B Czéh; T Michaelis; T Watanabe; J Frahm; G de Biurrun; M van Kampen; A Bartolomucci; E Fuchs
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-02       Impact factor: 11.205

7.  The hippocampus in patients treated with electroconvulsive therapy: a proton magnetic resonance spectroscopic imaging study.

Authors:  G Ende; D F Braus; S Walter; W Weber-Fahr; F A Henn
Journal:  Arch Gen Psychiatry       Date:  2000-10

8.  Metabolite ratios to assumed stable creatine level may confound the quantification of proton brain MR spectroscopy.

Authors:  Belinda S Y Li; Hao Wang; Oded Gonen
Journal:  Magn Reson Imaging       Date:  2003-10       Impact factor: 2.546

9.  Quantification of metabolic differences in the frontal brain of depressive patients and controls obtained by 1H-MRS at 3 Tesla.

Authors:  Stephan Gruber; Richard Frey; Vladimir Mlynárik; Andreas Stadlbauer; Angela Heiden; Siegfried Kasper; Graham J Kemp; Ewald Moser
Journal:  Invest Radiol       Date:  2003-07       Impact factor: 6.016

10.  Neurotrophic effects of electroconvulsive therapy: a proton magnetic resonance study of the left amygdalar region in patients with treatment-resistant depression.

Authors:  Nikolaus Michael; Andreas Erfurth; Patricia Ohrmann; Volker Arolt; Walter Heindel; Bettina Pfleiderer
Journal:  Neuropsychopharmacology       Date:  2002-10-10       Impact factor: 7.853

View more
  18 in total

Review 1.  Neurobiological Mechanisms of Stress Resilience and Implications for the Aged Population.

Authors:  Charlene Faye; Josephine C Mcgowan; Christine A Denny; Denis J David
Journal:  Curr Neuropharmacol       Date:  2018-03-05       Impact factor: 7.363

Review 2.  The Impact of Stress and Major Depressive Disorder on Hippocampal and Medial Prefrontal Cortex Morphology.

Authors:  Emily L Belleau; Michael T Treadway; Diego A Pizzagalli
Journal:  Biol Psychiatry       Date:  2018-10-10       Impact factor: 13.382

3.  Prefrontal Connectivity and Glutamate Transmission: Relevance to Depression Pathophysiology and Ketamine Treatment.

Authors:  Chadi G Abdallah; Christopher L Averill; Ramiro Salas; Lynnette A Averill; Philip R Baldwin; John H Krystal; Sanjay J Mathew; Daniel H Mathalon
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2017-10

4.  Prefrontal cortical GABA abnormalities are associated with reduced hippocampal volume in major depressive disorder.

Authors:  Chadi G Abdallah; Andrea Jackowski; João R Sato; Xiangling Mao; Guoxin Kang; Raminder Cheema; Jeremy D Coplan; Sanjay J Mathew; Dikoma C Shungu
Journal:  Eur Neuropsychopharmacol       Date:  2015-05-05       Impact factor: 4.600

5.  Antidepressant-like cognitive and behavioral effects of acute ketamine administration associated with plasticity in the ventral hippocampus to medial prefrontal cortex pathway.

Authors:  Julianne D Jett; Angela M Boley; Milena Girotti; Amiksha Shah; Daniel J Lodge; David A Morilak
Journal:  Psychopharmacology (Berl)       Date:  2015-05-20       Impact factor: 4.530

6.  Cellular metabolism changes in bilateral hippocampi in patients with herpes zoster.

Authors:  Jun Wang; Yanrong Yuan; Huili Liu; Yan Zhang; Yongxing Yan
Journal:  Am J Transl Res       Date:  2022-06-15       Impact factor: 3.940

Review 7.  Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine.

Authors:  Marc S Lener; Mark J Niciu; Elizabeth D Ballard; Minkyung Park; Lawrence T Park; Allison C Nugent; Carlos A Zarate
Journal:  Biol Psychiatry       Date:  2016-05-12       Impact factor: 13.382

8.  Metabotropic Glutamate Receptor 5 and Glutamate Involvement in Major Depressive Disorder: A Multimodal Imaging Study.

Authors:  Chadi G Abdallah; Jonas Hannestad; Graeme F Mason; Sophie E Holmes; Nicole DellaGioia; Gerard Sanacora; Lihong Jiang; David Matuskey; Ritvij Satodiya; Fabrizio Gasparini; Xin Lin; Jonathan Javitch; Beata Planeta; Nabeel Nabulsi; Richard E Carson; Irina Esterlis
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2017-04-06

9.  Glutamate and choline levels predict individual differences in reading ability in emergent readers.

Authors:  Kenneth R Pugh; Stephen J Frost; Douglas L Rothman; Fumiko Hoeft; Stephanie N Del Tufo; Graeme F Mason; Peter J Molfese; W Einar Mencl; Elena L Grigorenko; Nicole Landi; Jonathan L Preston; Leslie Jacobsen; Mark S Seidenberg; Robert K Fulbright
Journal:  J Neurosci       Date:  2014-03-12       Impact factor: 6.167

Review 10.  Glutamate and GABA Homeostasis and Neurometabolism in Major Depressive Disorder.

Authors:  Ajay Sarawagi; Narayan Datt Soni; Anant Bahadur Patel
Journal:  Front Psychiatry       Date:  2021-04-27       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.